Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2024-11-21 DOI:10.1111/apt.18409

Gian Paolo Caviglia, Piero Fariselli, Roberta D'Ambrosio, Piero Colombatto, Elisabetta Degasperi, Gabriele Ricco, Maria Lorena Abate, Giovanni Birolo, Giulia Troshina, Francesco Damone, Barbara Coco, Daniela Cavallone, Riccardo Perbellini, Sara Monico, Giorgio Maria Saracco, Maurizia Rossana Brunetto, Pietro Lampertico, Alessia Ciancio

引用次数: 0

Abstract

Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) has shown promising results as an HCC-predictive biomarker. We aimed to develop and validate a PIVKA-II-based model for HCC risk stratification in cirrhotic patients with SVR to DAA.

Abstract Image

查看原文本刊更多论文

开发并验证基于 PIVKA-II 的模型，用于对接受 DAA 成功治疗的 HCV 相关性肝硬化患者进行 HCC 风险分层

对直接作用抗病毒药物（DAA）有持续病毒学应答（SVR）的丙型肝炎病毒（HCV）相关肝硬化患者仍有罹患肝细胞癌（HCC）的风险。最近，维生素 K 缺乏或拮抗剂-II（PIVKA-II）诱导的血清蛋白作为 HCC 预测生物标志物显示出了良好的效果。我们旨在开发并验证一种基于 PIVKA-II 的模型，用于对接受 DAA 治疗并获得 SVR 的肝硬化患者进行 HCC 风险分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.